People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Biotechnology, Other Technology, Other Health Care, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Avidity Biosciences, Inc. | — | Biotechnology | Growth/Late | $527.8M | $5.7B | 2019 |
| RapidSOS, Inc. | — | Other Technology | Series C | $188.6M | $2.6B | 2016 |
| Plexium, Inc. | — | Biotechnology | Series C | $60.1M | $361.5M | 2025 |
| StrideBio, Inc. | — | Biotechnology | Series C | $57.7M | $1.5B | 2021 |
| RT Oncology Services Corp | — | Other Health Care | Series B | $56.5M | $5.0M | 2011 |
| OrphoMed, Inc. | — | Biotechnology | Series B | $24.6M | $864.1M | 2017 |
| High Plains Physicians, LLC | — | Other Health Care | Series B | $16.8M | $371.7M | 2013 |
| r.World, PBC | — | Other | Series A | $16.5M | $531K | 2022 |
| Circadian Risk Inc. | — | Other Technology | Series A | $7.0M | $17.1M | 2022 |
| Cheyenne Surgical Center Llc | — | Other Health Care | Seed | $3.2M | $75.4M | 2012 |
| Briar'S Creek Golf Llc | — | Other | Pre-Seed | $660K | $15.3M | 2009 |
Michael Martin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Michael Martin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Paul Johnson | 2 | 10 |
| John Romano | 2 | 2 |
| LEON CHEN | 1 | 15 |
| Nikitas Koutoupes | 1 | 14 |
| David Bailey | 1 | 11 |
| Richard Smith | 1 | 11 |
| Patrick Meenan | 1 | 10 |
| Clay Thorp | 1 | 10 |
| Michael Grey | 1 | 10 |
| Bruce Leak | 1 | 8 |
| Dan Nova | 1 | 8 |
| Todd Brady | 1 | 7 |
| TROY WILSON | 1 | 7 |
| Robert Hughes | 1 | 6 |
| Rob Hopfner | 1 | 6 |
| Mark Pacala | 1 | 5 |
| Karen Hong | 1 | 4 |
| Shaan Gandhi | 1 | 4 |
| Sapan Shah | 1 | 4 |
| Roderick Wong | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.